We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA: Assessment of Ranbaxy’s India Site Shows No Risk to Public Health
EMA: Assessment of Ranbaxy’s India Site Shows No Risk to Public Health
European regulators said they will reinstate a good manufacturing practice certification for Ranbaxy’s manufacturing facility in Toansa, India, following an inspection that found the generic drugmaker had addressed reported GMP violations.